|
GB1381872A
(en)
*
|
1971-06-22 |
1975-01-29 |
Fisons Ltd |
Pharmaceutical compositions for inhalation
|
|
BE787100A
(fr)
*
|
1971-08-06 |
1973-02-02 |
Beecham Group Ltd |
Composition pour le traitement de l'asthme
|
|
GB1410588A
(en)
*
|
1971-08-10 |
1975-10-22 |
Fisons Ltd |
Composition
|
|
DE2332663C2
(de)
*
|
1973-06-23 |
1986-07-31 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie
|
|
DE2535258C2
(de)
*
|
1974-08-10 |
1993-06-03 |
Fisons Plc, Ipswich, Suffolk |
Inhalierbares Medikament in Pelletform
|
|
US4161516A
(en)
*
|
1975-07-25 |
1979-07-17 |
Fisons Limited |
Composition for treating airway disease
|
|
IL51314A
(en)
*
|
1976-01-30 |
1980-03-31 |
Fisons Ltd |
Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
|
|
GB2077100B
(en)
*
|
1980-04-30 |
1985-04-24 |
Fisons Ltd |
Pharmaceutical compositions containing cromoglycates
|
|
BE891013A
(fr)
*
|
1980-11-05 |
1982-05-05 |
Fisons Ltd |
Compositions pharmaceutique
|
|
JPS59163313A
(ja)
*
|
1983-03-09 |
1984-09-14 |
Teijin Ltd |
経鼻投与用ペプチドホルモン類組成物
|
|
WO1993025193A1
(fr)
*
|
1992-06-12 |
1993-12-23 |
Teijin Limited |
Preparation pharmaceutique destinee a etre administree par les voies respiratoires
|
|
US6632456B1
(en)
|
1993-06-24 |
2003-10-14 |
Astrazeneca Ab |
Compositions for inhalation
|
|
US5830853A
(en)
|
1994-06-23 |
1998-11-03 |
Astra Aktiebolag |
Systemic administration of a therapeutic preparation
|
|
US6794357B1
(en)
|
1993-06-24 |
2004-09-21 |
Astrazeneca Ab |
Compositions for inhalation
|
|
ES2166786T3
(es)
*
|
1993-10-01 |
2002-05-01 |
Astrazeneca Ab |
Procedimiento i.
|
|
IS1736B
(is)
|
1993-10-01 |
1999-12-30 |
Astra Ab |
Aðferð og tæki sem stuðla að aukinni samloðun agna
|
|
GB9322014D0
(en)
|
1993-10-26 |
1993-12-15 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
NL9301851A
(nl)
*
|
1993-10-26 |
1995-05-16 |
Cordis Europ |
Cryo-ablatie catheter.
|
|
GB9404945D0
(en)
|
1994-03-15 |
1994-04-27 |
Glaxo Group Ltd |
Pharmaceutical composition
|
|
US6102036A
(en)
*
|
1994-04-12 |
2000-08-15 |
Smoke-Stop |
Breath activated inhaler
|
|
US6165976A
(en)
|
1994-06-23 |
2000-12-26 |
Astra Aktiebolag |
Therapeutic preparation for inhalation
|
|
DE4425255A1
(de)
|
1994-07-16 |
1996-01-18 |
Asta Medica Ag |
Formulierung zur inhalativen Applikation
|
|
JP4155594B2
(ja)
|
1994-12-22 |
2008-09-24 |
アストラゼネカ・アクチエボラーグ |
エアゾール製剤
|
|
EP1283035A3
(en)
|
1994-12-22 |
2003-03-19 |
AstraZeneca AB |
Therapeutic preparation for inhalation containing parathyroid hormone
|
|
US6524557B1
(en)
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
|
GB9501841D0
(en)
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
BR9809499A
(pt)
*
|
1997-05-27 |
2000-06-20 |
Direct Haler A S |
Inalador para medicamentos em pó
|
|
EP1119349B1
(en)
|
1998-08-18 |
2008-07-02 |
The Regents Of The University Of California |
Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
|
|
US7354894B2
(en)
*
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
PL352615A1
(en)
|
1999-06-05 |
2003-08-25 |
Innovata Biomed Ltd |
Delivery system
|
|
ITMI991582A1
(it)
|
1999-07-16 |
2001-01-16 |
Chiesi Farma Spa |
Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
|
|
GB9920839D0
(en)
|
1999-09-04 |
1999-11-10 |
Innovata Biomed Ltd |
Inhaler
|
|
EP1129705A1
(en)
*
|
2000-02-17 |
2001-09-05 |
Rijksuniversiteit te Groningen |
Powder formulation for inhalation
|
|
GB0009469D0
(en)
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
PE20011227A1
(es)
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
|
US20060194773A1
(en)
*
|
2001-07-13 |
2006-08-31 |
Paratek Pharmaceuticals, Inc. |
Tetracyline compounds having target therapeutic activities
|
|
EP1487417A4
(en)
*
|
2001-09-17 |
2010-03-17 |
Glaxo Group Ltd |
DRY POWDER DRUG FORMULATIONS
|
|
BR0214280A
(pt)
*
|
2001-11-19 |
2005-01-11 |
Becton Dickinson Co |
Composição farmacêuticas em forma particulada
|
|
GB0128148D0
(en)
|
2001-11-23 |
2002-01-16 |
Innovata Biomed Ltd |
Assembly
|
|
US6900317B2
(en)
|
2002-02-19 |
2005-05-31 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
|
|
DE10207026A1
(de)
*
|
2002-02-20 |
2003-08-28 |
Boehringer Ingelheim Kg |
Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
|
|
US20040014679A1
(en)
*
|
2002-02-20 |
2004-01-22 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
|
|
JP2006516531A
(ja)
*
|
2002-08-21 |
2006-07-06 |
ノートン ヘルスケアー リミテッド |
吸入組成物
|
|
US7763280B2
(en)
|
2002-11-28 |
2010-07-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Tiotropium containing powder formulation for inhalation
|
|
DE10317461A1
(de)
|
2003-04-16 |
2004-10-28 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung
|
|
DE10338407A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
|
|
DE10338399A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
|
|
DE10338402A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
|
|
US20050042179A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
|
|
US20050042178A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
|
|
US20050043247A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
|
|
DE10338403A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
|
|
PL1699434T3
(pl)
|
2003-09-02 |
2011-09-30 |
Norton Healthcare Ltd |
Sposób wytwarzania leku
|
|
TW200524577A
(en)
|
2003-11-04 |
2005-08-01 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
|
WO2005102429A1
(en)
|
2004-04-21 |
2005-11-03 |
Innovata Biomed Limited |
Inhaler
|
|
GB0409197D0
(en)
|
2004-04-24 |
2004-05-26 |
Innovata Biomed Ltd |
Device
|
|
AR050902A1
(es)
|
2004-04-27 |
2006-12-06 |
Glaxo Group Ltd |
Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
|
|
US7727962B2
(en)
*
|
2004-05-10 |
2010-06-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder comprising new compositions of oligosaccharides and methods for their preparation
|
|
US7723306B2
(en)
*
|
2004-05-10 |
2010-05-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
|
|
US7611709B2
(en)
*
|
2004-05-10 |
2009-11-03 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
|
|
DE102004048389A1
(de)
*
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
|
|
DE102004048390A1
(de)
*
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff
|
|
BRPI0606364A2
(pt)
*
|
2005-02-10 |
2010-03-23 |
Glaxo Group Ltd |
processo para formar lactose adequada para uso em uma formulaÇço farmacÊutica
|
|
WO2010010538A2
(en)
|
2008-07-24 |
2010-01-28 |
L'air Liquide-Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude |
Heteroleptic cyclopentadienyl transition metal precursors for deposition of transition metal-containing films
|
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
|
ES2739352T3
(es)
|
2009-02-26 |
2020-01-30 |
Glaxo Group Ltd |
Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
|
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
|
PT106094A
(pt)
|
2012-01-13 |
2013-07-15 |
Hovione Farmaciencia S A |
Administração por inalação de formulações com dose elevada
|
|
US20150165038A1
(en)
*
|
2012-02-10 |
2015-06-18 |
Arven llac Sanayi Ve Ticaret A.S. |
Compositions comprising muscarinic receptor antagonist and sorbitol
|
|
US10105316B2
(en)
|
2012-07-05 |
2018-10-23 |
Arven llac Sanayi Ve Ticaret A.S. |
Inhalation compositions comprising muscarinic receptor antagonist
|
|
US20150174064A1
(en)
*
|
2012-07-05 |
2015-06-25 |
Arven IIac Sanayi Ve Ticaret A.S. |
Compositions comprising muscarinic receptor antagonist and glucose anhydrous
|
|
US10111957B2
(en)
|
2012-07-05 |
2018-10-30 |
Arven Ilac Snayi ve Ticaret A.S. |
Inhalation compositions comprising glucose anhydrous
|
|
CN104869993B
(zh)
|
2012-10-25 |
2019-01-15 |
通用医疗公司 |
治疗阿尔茨海默病及相关疾病的组合疗法
|
|
GB201305825D0
(en)
|
2013-03-28 |
2013-05-15 |
Vectura Ltd |
New use
|
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
|
CN106061482A
(zh)
|
2013-10-08 |
2016-10-26 |
拉姆医疗公司 |
用于治疗淋巴管平滑肌瘤病的雷帕霉素
|
|
AU2014340182B2
(en)
|
2013-10-22 |
2019-05-23 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
|
NZ724756A
(en)
|
2014-04-04 |
2023-07-28 |
Ai Therapeutics Inc |
An inhalable rapamycin formulation for treating age-related conditions
|
|
CA2963085C
(en)
|
2014-10-07 |
2023-02-21 |
Lam Therapeutics, Inc. |
An inhalable rapamycin formulation for the treatment of pulmonary hypertension
|
|
US20190240194A1
(en)
|
2016-08-31 |
2019-08-08 |
The General Hospital Corporation |
Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
|
|
WO2019003118A1
(en)
|
2017-06-28 |
2019-01-03 |
Philip Morris Products S.A. |
CONTAINER WITH PARTICLES FOR USE WITH INHALER
|
|
CN111565711B
(zh)
|
2017-07-20 |
2023-01-03 |
阿茨治疗股份有限公司 |
色甘酸钠和布洛芬的粉末化制剂
|
|
KR20210071943A
(ko)
|
2018-07-02 |
2021-06-16 |
더 제너럴 하스피탈 코포레이션 |
크로몰린 소듐 및 α-락토스의 분말화된 제형
|
|
ES2953293T3
(es)
|
2018-08-07 |
2023-11-10 |
Norton Waterford Ltd |
Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
|
|
US12383528B2
(en)
|
2018-12-10 |
2025-08-12 |
The General Hospital Corporation |
Cromolyn esters and uses thereof
|
|
WO2021207060A1
(en)
|
2020-04-06 |
2021-10-14 |
The General Hospital Corporation |
Methods of treatment of coronavirus-induced inflammation conditions
|
|
EP4203945A1
(en)
|
2020-08-28 |
2023-07-05 |
Universität Linz |
Use of leoligin in the prevention of tissue damage
|
|
US12612391B2
(en)
|
2020-12-28 |
2026-04-28 |
The General Hospital Corporation |
Cromolyn derivatives and uses thereof
|
|
WO2026002967A1
(en)
|
2024-06-24 |
2026-01-02 |
Universität Linz |
Leoligin and derivatives thereof as calcium channel blockers for the prevention and/or treatment of related diseases
|